I came across a couple of articles from TheScientist magazine that talk about
PT-141 (bremelanotide) among other drugs that are seeking FDA approval for Female Sexual Dysfunction. Interesting reading. The opinion expressed is that the whole industry is waiting for the first one to get approved and once that happens the money needed will quickly appear and several of the the others will get hammered through the process in short order.
It gives you an interesting competitive market where all the players are rooting for each other. I still think Bremelanotide is the most likely candidate in terms of effectiveness but they may not be the first over the line. There is another drug that has just been rejected for the second time but, after they appealed, the FDA gave them some specific things they needed to look at before they applied again. This is seen as hopeful because it gives them specific hurdles they need to clear.
Here are those links...
That Loving FeelingLet’s Talk about SexBoth from The Scientist, 1 July 2014 and both by Megan Scudellari.